RxDoctor Payments Data

Tammy Poma

Adult Health · Chicago, ILNPI 1467670778

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $25,900 of the $31,875 with a category attached, or 81.3%. AstraZeneca accounts for 91.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $23,358 and has fallen 99.2% since, to $194 in 2025. Among adult health clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$31,875in general payments, 2019–2025

Across 72 payments — averaging $442.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$29K
  • Merck$2K
  • Ardelyx, Inc.$251
  • Bayer$239
  • Lilly USA, LLC$102
  • Akebia Therapeutics Inc$62
  • plus $90 from 2 others

What the payments were for

  • Speaking & faculty fees$25,90081%
  • Travel & lodging$3,53111%
  • Food & beverage$2,4448%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca49$29,003
Merck13$2,129
Ardelyx, Inc.4$251
Bayer2$239
Lilly USA, LLC1$102
Akebia Therapeutics Inc1$62
Novartis1$54
GSK1$36

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,875 in reported general payments places this provider in the 95th percentile of 553 adult health providers in Illinois.

See all adult health providers in Illinois

Medicare billing

Part B allowed, 2024
$13,805
Medicare patients
107
Services billed
191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate25$39,916
XphozahTenapanor Hcl13$35,287
Sevelamer Carbonate59$28,822
Calcium Acetate59$5,258
Nifedipine ErNifedipine15$1,255
Hydroxyzine Hcl23$345
Torsemide25$334
Carvedilol32$290
Pantoprazole Sodium14$228
Irbesartan16$117
Amlodipine Besylate32$96

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$29,003$39,91625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 553 adult health providers in Illinois.

Other adult health in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →